T. Klopsch

Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?

Anja Strangfeld, Maria Eveslage, Matthias Schneider et al. · Annals of the Rheumatic Diseases · 2011 · 362 citations · Full text

Medicine, Immunology, Pharmacotherapy +13

Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low – results from RABBIT, the German biologics register

Joachim Listing, Anja Strangfeld, Rolf Rau et al. · Arthritis Research & Therapy · 2006 · 173 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +17

Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study

Joachim Sieper, T. Klopsch, Michael Richter et al. · Annals of the Rheumatic Diseases · 2007 · 147 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis

Adrian Richter, Joachim Listing, M Schneider et al. · Annals of the Rheumatic Diseases · 2015 · 111 citations · Full text

Medicine, Immunology, Internal Medicine +17

Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes

Eugen Feist, Xenofon Baraliakos, Frank Behrens et al. · Rheumatology and Therapy · 2022 · 16 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +14